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Summary
The programmed cell death 1 (PD-1) receptor plays a major role in
regulating T cell activation. Our aim was to determine how inflammation
influences PD-1-mediated T cell suppression. Flow cytometry analysis of
rheumatoid arthritis (RA) and psoriatic arthritis (PsA) synovial fluid (SF)
mononuclear cells showed an increase in the percentage of PD-11 cells
within the CD41 and CD81 T cell compartment compared to paired
peripheral blood (PB). Upon in-vitro T cell receptor (TCR) stimulation of
healthy control (HC) CD41 T cells in the presence of plate-bound PD-L1fc
chimera, significantly decreased proliferation and interferon (IFN)-g
secretion was observed. In contrast, CD41 T cells from RA and PsA PB and
SF appeared resistant to such PD-1-mediated inhibition. Addition of the
proinflammatory cytokines tumour necrosis factor (TNF)a, interleukin
(IL)-6 and IL-1b, which were increased in RA and PsA SF compared to
osteoarthritis (OA) SF, consistently abrogated PD-1-mediated suppression
in HC CD41 T cell cultures. This effect was reversed by inhibitors of these
cytokines. Soluble PD-1 (sPD-1) levels were increased in cell culture
supernatants from TNFa and IL-6-stimulated cultures compared to
untreated controls, and also in RA and PsA, but not in OA, serum and SF.
Functionally, addition of sPD-1fc counteracted PD-1-mediated suppression
of HC CD41 T cells, and increased T cell proliferation in HC CD41 T cell/
monocyte co-cultures. These in-vitro findings indicate that CD41 T cells
from patients with RA and PsA show increased resistance to PD-1-mediated
suppression, which may be explained in part by the presence of soluble PD-
1 in the inflammatory environment.
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Introduction
The programmed cell death 1 (PD-1) receptor, a trans-
membrane protein and member of the B7 family, plays a
critical role in T cell regulation [1]. PD-1 is expressed on T
cells, where its expression increases within the first 24 h of
T cell activation and decreases with antigen clearance
[2–4]. Upon ligation of PD-1 by its ligands (PD-L1/B7-H1
and PD-L2/B7-DC), T cell responses are down-regulated
[5,6]. PD-1 ligation leads to inhibition of the phosphatidyl-
inositol 3-kinase (PI3K) pathway, resulting in reduced Akt
(protein kinase B) phosphorylation and reduced expression
of transcription factors GATA-3, T-bet and Eomes [7,8].
The overall effect of PD-1 ligation is decreased T cell activa-
tion and cytokine production [9–12]. The clinical relevance
of PD-1 in immune regulation is evidenced by the recent
success of PD-1 blockade in the treatment of certain end-
stage cancers, leading to reduced tumour burden and
enhanced anti-tumour immunity in a considerable number
of patients [13,14]. Conversely, in inflammatory conditions
it has been documented that disruption of the PD-1 gene
(pdcd1) in mice leads to lupus-like syndrome, proliferative
arthritis, diabetes, autoimmune cardiomyopathy and
increased susceptibility to collagen-induced arthritis (CIA)
[15–20]. In humans, polymorphisms in the PDCD1 gene
have been associated with susceptibility to rheumatoid
arthritis (RA), ankylosing spondylitis (AS), systemic lupus
erythematosus (SLE), multiple sclerosis (MS) and type 1
diabetes mellitus [21–25].
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Several investigators have shown that frequencies of PD-
11 CD41 T cells are increased in RA synovial fluid com-
pared to RA peripheral blood (PB) and healthy control
(HC) PB [20,26,27]. However, despite high levels of this
inhibitory receptor at the site of inflammation, the
immune system seems unable to regulate persistent T cell
activation and cytokine production. This poses the ques-
tion as to whether the PD-1 pathway is impaired during
inflammation. An indication of a defective PD-1 pathway
in RA comes from a study indicating that RA synovial fluid
(SF) CD41 T cells show reduced PD-1-mediated inhibition
compared to RA PB cells [20]. This suggests that under
conditions of chronic inflammation the PD-1 pathway is
modulated. Thus far, little is known regarding the PD-1/
PD-L1 pathway in the context of psoriatic arthritis (PsA).
PsA and RA, while sharing a number of common patholog-
ical features, are two distinct diseases with serological,
genetic and radiological differences [28]. Here we deter-
mined the expression of PD-1 on T cells from PB and SF of
patients with RA or PsA, and investigated how inflamma-
tory mediators associated with RA and PsA affect PD-1-
mediated T cell suppression. Our data indicate that CD41
T cells from patients with RA and PsA are compromised in
their PD-1-mediated inhibition and reveal a potential role
for soluble PD-1 (sPD-1) in the aberrant PD-1-mediated
regulation in these diseases.
Materials and methods
Patients and healthy volunteers
Heparinized PB and matched SF samples were obtained
from patients with RA and PsA recruited from the rheuma-
tology out-patient clinic at Guy’s and St Thomas’ Hospital
NHS Trust (London, UK). Information on clinical and
demographic parameters is provided in Supporting infor-
mation, Table 1. HC subjects were recruited from among
local student and staff volunteers. Written informed con-
sent was received from all participants. Ethics approval was
given by the Bromley Research Ethics Committee (approval
no. 06/Q0705/20) for HC, RA and PsA and by the Guy’s
Research Ethics Committee (approval no. 01/05/01) for
osteoarthritis (OA). All samples were collected in compli-
ance with the Declaration of Helsinki.
PBMC, SFMC and cell subset isolation
PB mononuclear cells (PBMC) and SF mononuclear cells
(SFMC) were isolated by LymphoprepTM (Axis-Schield,
Oslo, Norway) density-gradient centrifugation. Cell subsets
were isolated by magnetic separation (Miltenyi Biotech,
Bergisch Gladbach, Germany and Dynabeads Thermo-
fisher, Paisley, UK) and purity was determined by flow
cytometry. CD41 T cells (purity range 95–99%) were iso-
lated by negative isolation from PBMC or SFMC or from
the CD14-depleted cell fractions following the manufac-
turers’ instructions. CD141 monocytes (purity range 96–
98%) were selected positively using CD14 MicroBeads
(Miltenyi Biotec).
Cell culture
Cell subsets were cultured for 5 days in culture medium
(RPMI-1640; GIBCO, Paisley, UK), supplemented with 1%
penicillin/streptomycin, 1% L-glutamine (GIBCO) and 10%
heat-inactivated fetal calf serum (GIBCO) and maintained at
378C and 5% CO2 atmosphere. Cells were stimulated with
either plate-bound anti-CD3 monoclonal antibody (mAb)
(OKT3; Janssen-Cilag Ltd, High Wycombe, UK) (15 mg/
ml) in CD41 T cell only cultures or with soluble anti-CD3
mAb (OKT3; Janssen-Cilag Ltd) (100 ng/ml) in CD41
T cell/CD141monocyte co-cultures.
Flow cytometry analysis of cell frequency and
phenotype
For ex-vivo analysis of frequency and phenotype of each cell
subset, PBMC or SFMC were stained extracellularly for 30
min at 48C using different combinations of the following
antibodies: fluorescein isothiocyanate (FITC)-conjugated
CD279 (PD-1; BioLegend, Cambridge, UK), phycoerythrin
(PE)-conjugated CD274 (PD-L1; BD Pharmingen, Oxford,
UK), PE/cyanin 7 (Cy7)-conjugated CD3 (Biolegend), peridi-
nin chlorophyll (PerCP)/Cy55-conjugated CD4 (Biolegend),
PacBlue-conjugated CD8 (Biolegend), allophycocyanin
(APC)-conjugated CD8 (Biolegend) and Vio770-conjugated
CD14 (Miltenyi Biotech). Following surface staining, cells
were fixed in 2% paraformaldehyde (PFA) for 15 min at 48C,
washed twice and acquired on a BD fluorescence activated
cell sorter (FACS)Calibur or a BD FACSCanto II. Data were
analysed using FlowJo software (version 7.6.5; Tree Star, Ash-
land, OR, USA).
T cell proliferation and PD-1 ligation assays
96 well flat-bottomed plates (Costar, Corning Inc., Corn-
ing, NY, USA) were coated with anti-CD3 mAb (OKT3;
Janssen-Cilag Ltd) (15 mg/ml) and with either PD-L1fc or
immunoglobulin (Ig)G1fc (R&D Systems, Abingdon, UK)
(ranging from 0 to 5 mg/ml according to the experiment) in
phosphate-buffered saline (PBS) solution (Sigma Aldrich,
Poole, UK) for 4 h at 378C and 5% CO2. Plates were
washed twice with PBS before cells were added for culture.
CD41 T cells were isolated from cryopreserved HC PBMC,
RA and PsA PBMC and RA and PsA SFMC and plated at a
concentration of 1 3 105 cells per well in a final volume of
200 ll of culture medium. In some cultures, human
recombinant tumour necrosis factor (hrTNF)a, human
recombinant interleukin (hrIL)-6 or hrIL-1b (all at 10 ng/
ml; R&D Systems) were added in the absence or presence
of anti-TNFa drug adalimumab (AbbVie, Chicago, IL,
USA), anti-IL-6R drug tocilizumab (Roche, Basel,
D. Bommarito et al.
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Switzerland) or anti-IL-1b mAb (R&D Systems) (all at 1
mg/ml). In some cultures, HC CD41 T cells were cultured
in PD-L1fc (0, 01 and 1 mg/ml)-coated plates in the pres-
ence of soluble PD-1fc (05 and 1 mg/ml; R&D Systems). In
other experiments, freshly isolated HC CD41 T cells and
autologous CD141 monocytes (used as a source of PD-L1
ligand) were co-cultured in 96-well flat-bottomed plates
(Costar, Corning Inc.) at 1 : 1 ratios (total cells per well
1 3 105) in culture medium containing 100 ng/ml soluble
anti-CD3 mAb and soluble PD-1fc or IgG1fc (0, 025, 05
and 1 mg/ml). In all assays, at day 4, cells were pulsed with
[3H]-thymidine (025 lCi/well) (GE Healthcare, Little
Chalfont, UK) and T cell proliferation was assessed after
18 h (on day 5) using a Topcount scintillation counter
(Perkin Elmer, Cambridge, UK). Proliferation was deter-
mined and expressed as counts per minute (cpm) and as
suppression of T cell proliferation (%) according to the fol-
lowing formula: [(medium only condition2PD-L1fc con-
dition)/medium only condition] 3 100.
Detection of soluble cytokines and soluble PD-1
CD41 T cell culture supernatants were collected at day 5
and stored at 2808C. IFN-g levels were determined by
enzyme-linked immunosorbent assay (ELISA) using the
ELISA MAXTM standard set (Biolegend). Levels of sPD-1
were determined by human PD-1 DuoSet ELISA (R&D
Systems). Serum samples from HC donors and serum and
paired cell-free SF samples from patients with OA, RA or
PsA were collected and stored at 2808C until analysed by
ELISA (for sPD-1; R&D Systems) or Bio-Plex ProTM (for
TNFa, IL-6 and IL-1b; Bio-Rad Laboratories) on the Lumi-
nex FlexMap 3D platform (Luminex Corporation, Austin,
TX, USA). All assays were performed according to the
manufacturers’ protocols.
RNA extraction and real-time–quantitative
polymerase chain reaction (RT–qPCR)
Total RNA was isolated using the ReliaPrepTM RNA cell
Miniprep System (Promega, Southampton, UK) according
to the manufacturer’s protocol. cDNA synthesis was per-
formed using a high-capacity cDNA reverse transcription
kit (Applied Biosystems, Foster City, CA, USA) and mRNA
expression of PD-1Dex3 was determined using the Sensi-
MixTM SYBR No-ROX Kit (Bioline, London, UK). Data
were collected and analysed on a Rotor-Gene Q thermocy-
cler (Qiagen, Hilden, Germany). The b-actin gene was
used as an endogenous control and relative gene expression
was expressed as 2–DDCT. PCR primer pairs (IDT, Leuven,
Belgium) were as follows: PD-1Dex3, 50-AGGGTGACAGG
GACAATAGG-30 and 50-CCATAGTCCACAGAGAACAC-
30, b-actin, 50-ATTGGCAATGAGCGGTTC-30 and 50-
CGTGGATGCCACAGGACT23’.
Statistical analysis
Significance testing was performed with GraphPad Prism
software (version 7; GraphPad, La Jolla, CA, USA) using
the appropriate statistical tests, as indicated in the figure
legends.
Results
PD-11 T cell frequencies are increased in RA and PsA
synovial fluid compared to peripheral blood
First, we investigated the frequencies of PD-11 cells among
T cells in PB and paired SF from patients with RA and PsA.
Significantly increased percentages of PD-11 cells were
found within SF CD41 T cells (identified either by
CD31CD14–CD41 cells or CD31CD8– cells) compared to
PB (Fig. 1a,b). In addition, increased percentages of PD-11
cells were found within the SF CD81 T cell compartment
in both RA and PsA (Fig. 1c,d).
PD-1 ligation reduces proliferation of CD41 T cells
from healthy donors, but not CD41 T cells from
patients with RA or PsA
To investigate whether the PD-1 expression is func-
tional in RA and PsA, we set up a PD-1 ligation assay
using anti-CD3 and PD-L1fc (or IgG1fc as control)-
coated plates, based on previously described protocols
[9,29,30]. As expected, PD-1 ligation resulted in a sig-
nificant and dose-dependent reduction of healthy con-
trol PB-derived CD41 T cell proliferation, while no
effect was observed in the presence of IgG1fc control
(Fig. 2a,b). IFN-g production was also inhibited in a
PD-L1fc dose-dependent fashion (Supporting informa-
tion, Fig. S1a). We then compared PD-1 ligation of
PB-derived CD41 T cells from healthy donors and
patients with RA in parallel experiments. In contrast to
the suppressive effects on T cell proliferation observed
upon PD-1 ligation of CD41 T cells from healthy
donors, CD41 T cells from patients with RA appeared
to be resistant to PD-1-mediated suppression of T cell
proliferation (Fig. 2c,d). Next, we cultured CD41 T
cells from the blood and synovial fluid from patients
with RA and PsA with increasing doses of plate-bound
PD-L1fc. Even at the highest dose of PD-L1fc (5 mg/ml)
we did not detect a decrease in T cell proliferation
upon PD-1 ligation (Fig. 2e,f). Similarly, when RA and
PsA cell culture supernatants were tested for IFN-g
production, we could not detect a consistent decrease
in the levels of IFN-g (Supporting information, Fig.
S1b). These data indicate that CD41 T cells from the
blood and synovial fluid of patients with RA or PsA
are resistant to PD-1 ligation compared to healthy
control cells.
Inflammation modulates PD-1 mediated suppression of CD41 T cells
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TNFa, IL-6 and IL-1b counteract PD-1-mediated
suppression of CD41 T cell proliferation
Because RA and PsA CD41 T cells, especially those from the
synovial fluid, are derived from a proinflammatory environ-
ment, we sought to examine how inflammatory cytokines
may influence PD-1-mediated T cell suppression. First, we
determined the levels of TNFa, IL-6 and IL-1b in RA and
PsA-derived sera and paired SF, compared to healthy serum
and serum and SF from disease control patients with osteoar-
thritis (OA). Increased levels of all three cytokines were
detected in both RA and PsA SF when compared to HC
serum or OA SF (Fig. 3a,b). These data confirm the inflam-
matory nature of SF in both RA and PsA. In the analysed RA
and PsA sera, we only found mild increases of TNFa and IL-
6 compared to healthy or OA control serum.
Next, we assessed whether the presence of TNFa, IL-6 or
IL-1b had a functional impact on PD-1-mediated suppres-
sion of CD41 T cell proliferation. HC CD41 T cells were cul-
tured with increasing concentrations of PD-L1fc (0, 01 and 1
mg/ml) in the absence or presence of TNFa, IL-6 or IL-1b (10
ng/ml). To block the effect of the cytokines, the anti-TNFa
drug adalimumab, anti-IL-6R drug tocilizumab or anti-IL-1b
mAb (1 mg/ml) were added at the beginning of the culture
where indicated. Addition of each individual cytokine was
able to abrogate the suppressive effects of PD-1 ligation on
CD41 T cell proliferation at both 01 and 1 mg/ml PD-L1
concentrations (Fig. 3c). In each sample tested, adalimumab,
tocilizumab and anti-IL-1b mAb were able to reverse these
cytokine-mediated effects completely. Together, these data
indicate that the RA- and PsA-associated inflammatory cyto-
kines TNFa, IL-6 and IL-1b can counteract the suppressive
effects of PD-1 ligation on CD41 T cells, at least in vitro.
Soluble PD-1 (sPD-1) is induced in vitro by TNFa and
IL-6 in HC CD41 T cell cultures and can be detected in
serum and SF of both RA and PsA patients
Having demonstrated that TNFa, IL-6 and IL-1b can be
detected in RA and PsA patients and that each of these
Fig. 1. Programmed cell death 1 (PD-1)1 T cell frequencies are increased in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) synovial fluid
compared to peripheral blood. Frequencies of PD-11 T cells were analysed ex vivo by flow cytometry in peripheral blood mononuclear cells
(PBMC) and synovial fluid mononuclear cells (SFMC) from RA and PsA patients. (a) Contour plot of CD31CD14–CD41PD-11 cells from
paired PBMC and SFMC of one representative PsA donor. (b) Cumulative data showing percentage of PD-11 cells within CD31CD8– or
CD31CD14–CD41 (RA n5 10; PsA n5 11) PB and SF cell populations. (c) Contour plot of CD31CD81PD-11 cells from paired PBMC and
SFMC of one representative RA donor. (d) Cumulative data showing percentage of PD-11 cells within CD31CD81 (RA n5 7; PsA n5 8) PB
and SF cell populations. Data were analysed by Wilcoxon matched-pairs signed-rank test. *P< 005, **P< 001 and ***P< 0001. Isotype control
staining showed a similar result to fluorescence minus 1 (FMO) staining (Supporting information, Fig. S5).
D. Bommarito et al.
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Fig. 2. Programmed cell death-1 (PD-1) ligation reduces proliferation of CD41 T cells from healthy donors but not CD41 T cells from patients with
rheumatoid arthritis (RA) or psoriatic arthritis (PsA). (a–f) CD41 T cells were isolated from healthy control (HC) peripheral blood mononuclear cells
(PBMC) and RA and PsA PBMC and synovial fluid mononuclear cells (SFMC) and cultured for 5 days in plates precoated with anti-CD3monoclonal
antibody (mAb) (OKT3; 15 mg/ml) and PD-L1fc/IgG1fc (0, 01, 1, 2 and 5 mg/ml). Proliferation was assessed on day 5 by [3H]-thymidine incorporation.
(a) HC CD41 T cell proliferation (cpm) and (b) suppression of proliferation following PD-1 ligation by PD-L1fc (n5 7) or immunoglobulin (Ig)G1fc
(n5 5–7). (c) Cell proliferation (cpm) and (d) suppression of proliferation of CD41 T cells isolated from HC and RA PBMC (n5 9) in presence of PD-
L1fc. (e) Cell proliferation (cpm) and (f) suppression of proliferation of CD41 T cells isolated from RA and PsA PBMC and paired SFMC in presence of
PD-L1fc (n5 3 RA PB/SF; n5 4 PsA PB/SF). Data were analysed by Friedman test with Dunn’s multiple comparison test. *P< 005, **P< 001 and
***P< 0001. Data in (b,d,f) show mean6 standard error of the mean.
Inflammation modulates PD-1 mediated suppression of CD41 T cells
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cytokines abrogates PD-L1fc activity in vitro, we sought to
identify a possible underlying mechanism. ELISA analysis
of HC CD41 T cell supernatants from cytokine-stimulated
cultures revealed that both TNFa and IL-6 were able to
induce sPD-1 compared to medium-only conditions (Fig.
4a,b). No significant increase in sPD-1 was observed in IL-
1b-stimulated cultures (Fig. 4c). This increase in sPD-1
was abrogated in the presence of adalimumab or
Fig. 3. Tumour necrosis factor (TNF)a,
interleukin (IL)-6 and IL-1b counteract
the programmed cell death-ligand 1
(PD-L1)-mediated suppression of
healthy control (HC) CD41 T cell
proliferation. (a,b) Levels of
proinflammatory cytokines TNFa, IL-6
and IL-1b in paired rheumatoid
arthritis (RA) and psoriatic arthritis
(PsA) serum/synovial fluid (SF)
(n5 12), in osteoarthritis (OA) (disease
control) serum/SF (n5 3–4) and in HC
serum (n5 7). Wilcoxon’s matched-
pairs signed-rank test for RA/PsA
serum versus RA/PsA SF and Mann–
Whitney test for RA/PsA SF versus HC
serum or OA SF. *P< 005, **P< 001
and ***P< 0001. (c) Plates were coated
with PD-L1fc at the indicated
concentrations, and PD-L1-mediated
suppression of proliferation by CD41 T
cells from HC PB was assessed in
absence (medium, M) or presence of 10
ng/ml of TNFa (n5 9), IL-6 (n5 5) or
IL-1b (n5 6) 6 anti-TNFa
(adalimumab; ADA), anti-IL-6R
(tocilizumab; TOC) and anti-IL-1b (all
at 1 mg/ml). Data in (c) were analysed
by Wilcoxon matched-pairs signed-rank
test. *P< 005 and **P< 001.
D. Bommarito et al.
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Fig. 4. Soluble programmed cell death-1 (sPD-1) is induced in vitro by tumour necrosis factor (TNF)a, interleukin (IL)-6 in HC CD41 T cell
cultures and can be detected in serum and synovial fluid (SF) of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients. (a–c) sPD-1
levels in supernatants of healthy control (HC) CD41 T cells stimulated with (a) TNFa (10 ng/ml) or TNFa1 adalimumab (ADA; 1 mg/ml)
(n 5 7), (b) IL-6 (10 ng/ml) or IL-61 tocilizumab (TOC; 1 mg/ml) (n 5 5–-7) and (c) IL-1b (10 ng/ml) or IL-1b1 anti-IL-1b (anti-IL-1b; 1
mg/ml) (n 5 5). (d) sPD-1 levels (median with interquartile range) in RA and PsA paired serum/synovial fluid (SF) and osteoarthritis (OA)
serum/SF (OA, n 5 3–4; RA, n 5 17; PsA, n 5 18). (e) sPD-1 levels (median with interquartile range) in control disease OA (n 5 3–4), RA
(n 5 5) and PsA (n 5 6–7) serum and SF of patients treated with TNFi versus non-TNFi therapy. Data in (a,b,c,e) were analysed by Mann–
Whitney test while data in (d) were analysed by Kruskal–Wallis test with Dunn’s multiple comparison test. *P< 005, **P< 001, ***P< 0001.
Inflammation modulates PD-1 mediated suppression of CD41 T cells
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tocilizumab. Quantitative PCR analysis of HC CD41 T cells
from the same TNFa- and IL-6-stimulated cultures
revealed increases of the PD-1Dex3 splice variant (Support-
ing information, Fig. S2). These results are in line with a
previous study from another group reporting that TNFa
promotes sPD-1 expression [31] but also identify IL-6 as
an inducer of sPD-1 and PD-1Dex3.
In addition, ELISA analysis revealed that sPD-1 was
detectable in none of three OA serum and none of four OA
SF samples, while it was detected at high levels in 13 of 17
RA and 13 of 18 PsA serum and SF samples (Fig. 4d). Addi-
tionally, cross-sectional analysis of serum and SF from
patients with RA or PsA undergoing TNF-inhibitor (TNFi)
therapy revealed lower levels of sPD-1 when compared to
patients not receiving TNFi therapy (Fig. 4e). These data
show that proinflammatory cytokines such as TNFa and
IL-6 can modulate the amount of sPD-1 in vitro and that
TNFi therapy might modulate sPD-1 levels in the serum
and SF of patients with inflammatory arthritis.
sPD-1 modulates PD-1-mediated suppression of HC
CD41 T cells and induces proliferation in CD41 T
cell/CD141 monocyte co-cultures
To investigate whether sPD-1 is able to modulate PD-1/
PD-L1 interactions, we first tested if sPD-1fc itself pro-
motes T cell proliferation of anti-CD3 stimulated HC
CD41 T cells cultured in the absence of PD-L1fc. In these
experimental conditions, sPD-1fc did not induce any
increase in cell proliferation (Supporting information, Fig.
S3), suggesting no direct effect on HC CD41 T cells. We
then cultured HC CD41 T cells in the presence of increas-
ing amounts of PD-L1fc ligand in the absence or presence
of sPD-1fc chimera (05 or 1 mg/ml). In PD-L1fc precoated
plates, addition of sPD-1fc was able to abrogate the activity
of the ligand in a dose-dependent fashion, resulting in less
efficient suppression of T cell proliferation when compared
to medium only (Fig. 5a,b). These data indicate that in a
CD41 T cell-only culture system, sPD-1 is able to modulate
negatively an otherwise functional PD-1/PD-L1
interaction.
To investigate further the ability of sPD-1 to modulate
the PD-1/PD-L1 interaction, we set up a co-culture system
using HC CD41 T cells and autologous CD141 cells as a
source of natural PD-L1. The ability of HC CD141 cells to
express PD-L1 was tested by flow cytometry by culturing
the cells overnight with 10 ng/ml of IFN-g, a known
inducer of PD-L1 [27,32] (Supporting information, Fig.
S4). Freshly isolated HC CD41 T cells and autologous
monocytes were cultured at a 1 : 1 ratio with soluble anti-
CD3 mAb (100 ng/ml) in the absence or presence of
increasing doses of sPD-1 or IgG1fc control (025, 05 and
1 mg/ml). Addition of sPD-1fc led to a significant dose-
dependent increase in T cell proliferation compared to
control-treated cells (Fig. 5c,d). These data indicate that
soluble PD-1 receptor can modulate PD-1 ligation in both
an artificial system (PD-L1fc precoated plates) as well as in
a more physiological context (in the presence of PD-L11
APC).
Discussion
The present study provides evidence for compromised PD-
1 mediated suppression in CD41 T cells from patients with
RA and PsA. Our study identifies the proinflammatory
cytokines TNFa, IL-6 and IL-1b as negative modulators of
PD-1-mediated T cell suppression in vitro and demon-
strates that sPD-1 is capable of interfering with effective
PD-1 ligation. To our knowledge, this is the first study to
examine PD-1 function in RA and PsA simultaneously, and
to provide evidence that the inflammatory milieu of these
two diseases has a role in modulating PD-1 ligation.
We show that the frequencies of PD-11 cells within
CD41 and CD81 T cell subsets are increased significantly
in the synovial fluid from patients with RA or PsA when
compared to peripheral blood, thus extending the findings
from previous studies focusing only on RA [20,26,27,33].
The increase in the frequencies of PD-11 T cells suggests
that in RA and PsA PD-1 might have a role in regulating T
cell effectors, especially at the site of inflammation. How-
ever, despite this increased frequency of PD-11 T cells,
inflammation persists, suggesting that this pathway is
impaired in these diseases.
Thus far, only limited data exist regarding PD-1 function
in inflammatory arthritis. One study using a PD-L1fc chi-
mera demonstrated that PD-1 ligation inhibited cell prolif-
eration and IFN-g production by CD41 T cells from
peripheral blood of RA patients, but that synovial fluid
CD41 T cells required higher concentrations of PD-L1fc to
achieve similar levels of inhibition [20]. The authors specu-
lated that the inflammatory milieu found in the RA joint
might be accountable for reduced PD-1-mediated suppres-
sion, as they showed that addition of cell-free SF to RA PB
CD41 T cells modulated PD-1 ligation negatively [20].
However, no specific mediator of the effect was identified.
It has been shown previously that the common gamma
chain cytokines IL-2, IL-7 and IL-15, as well as CD28 co-
stimulation, can interfere with PD-1 cross-linking via
pSTAT-5 activation [9,29]. In our study, we show that in
both RA and PsA, CD41 T cells from the blood and syno-
vial fluid are more resistant to PD-1 ligation in terms of
suppression of T cell proliferation and IFN-g production
when compared to healthy cells. We show that the proin-
flammatory cytokines TNFa, IL-6 and IL-1b are found at
increased levels in RA and PsA SF, and can reduce PD-1-
mediated suppression of proliferation in CD41 T cells
from healthy donors. Inhibitors of these cytokines can
counteract this effect. These findings provide further evi-
dence that the presence of certain proinflammatory
D. Bommarito et al.
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cytokines can be critical in determining the outcome of
PD-1 engagement during the immune response.
Mechanistically, our data demonstrate that TNFa and
IL-6, but not IL-1b, induce the secretion of sPD-1 by
CD41 T cells, and that sPD-1 levels are increased signifi-
cantly in the serum and SF of patients with RA or PsA
compared to OA. The latter data support and extend two
recent studies that showed that sPD-1 can be detected in
the serum and SF from patients with RA [27,34]. In these
studies sPD-1 serum levels correlated positively with the
Disease Activity Score (DAS28), the presence of rheuma-
toid factor, and with levels of TNFa in the RA SF but not
the serum [27,34]. Recent studies showed that expression
of the PD-1Dex3 variant is observed in T cells from
patients with RA, but only minimally in T cells from
patients with OA or from HC [27,31]. PD-1Dex3 is a splice
Fig. 5. Soluble programmed cell death 1 (sPD-1) modulates PD-1-mediated suppression of healthy control (HC) CD41 T cells and induces
proliferation in CD41 T cell/CD141 monocyte co-cultures. (a) Proliferation and (b) suppression of proliferation of HC CD41 T cells cultured in
anti-CD3 monoclonal antibody (mAb) (OKT3) and PD-L1fc pre-coated plates with or without soluble PD-1fc (0.5 and 1 mg/ml) (n 5 9–10). (c)
Proliferation and (d) suppression of proliferation of HC CD41 T cells cultured with autologous CD141 monocytes at a 1 : 1 ratio (n 5 7) in
presence of soluble anti-CD3 mAb (100 ng/ml) and soluble PD-1fc/IgG1fc control (0, 025, 05 and 1 mg/ml). Data were analysed by Friedman’s
test with Dunn’s multiple comparison test (a,b) and Wilcoxon’s signed-rank test (c,d). *P< 005 and ***P< 0001.
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variant of PD-1, which lacks the transmembrane domain
and whose putative translational product is a soluble form
of PD-1 [34,35]. It was shown that TNFa, IL-17 and IFN-g
can increase PD-1Dex3 splice variant mRNA expression in
healthy human CD41 T cells [31]. Our data indicate that
in addition to those cytokines, sPD-1 protein expression
and PD-1Dex3 splice variant mRNA expression can also be
regulated by IL-6. Furthermore, preliminary analysis from
a cross-sectional investigation of PsA and RA serum and SF
suggests that patients treated with TNFi therapy have lower
sPD-1 levels compared to patients not treated with TNFi
therapy. Further longitudinal studies on patients treated
with adalimumab or tocilizumab are required, however,
before conclusive statements can be made regarding the
effect of biologics on sPD-1 levels.
Our data demonstrate that the inflammatory cytokines
TNFa and IL-6 can lead to increased levels of PD-1Dex3
splice variant as well as sPD-1. It is possible that a certain
amount of PD-1 might also be released from the cell mem-
brane via other mechanisms. The presence of high levels of
certain metalloproteinases (MMPs) such as MMP-9 and
MMP-13 has been described previously in inflammatory
arthritis [36,37], and it has been shown recently that
expression of the PD-1 ligands PD-L1 and PD-L2 in infant
foreskin fibroblasts can be regulated through proteolytic
cleavage by MMPs [38]. Future studies may reveal whether
such an MMP-mediated proteolytic cleavage may also con-
tribute to generation of soluble PD-1.
Notably, we show, using a recombinant PD-1 chimera,
that sPD-1 is functionally able to counteract PD-L1fc-
mediated suppression of healthy CD41 T cell proliferation,
and to enhance CD41 T cell proliferation when co-
cultured with CD141 monocytes that can naturally express
PD-L1. Importantly, recent studies in autoimmune hepati-
tis [39] and cutaneous systemic sclerosis [40] support the
notion that sPD-1 might interfere with the PD-1 pathway,
thereby disrupting T cell regulation.
Collectively, our data indicate that CD41 T cells from the
PB and SF of patients with chronic RA or PsA are more
resistant to PD-1-mediated regulation than CD41 T cells
from healthy individuals. We show that the proinflamma-
tory cytokines TNFa, IL-6 and IL-1b, which are present at
increased levels in the inflamed joints of RA and PsA
patients, are capable of negatively modulating PD-1 ligation
in vitro. Finally, we show that TNFa and IL-6 are capable of
inducing sPD-1 in HC CD41 T cells and that sPD-1 modu-
lates T cell proliferation by interfering with PD-1 ligation.
Thus, our findings provide new evidence that the inflam-
matory environment of the RA and PsA joint compromises
PD-1/PD-L1-mediated T cell regulation.
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Supplementary Table 1. Demographic and clinical
parameters of the patients included in the study. Some
samples were used for flow cytometry or functional assays
only, whilst other samples were only used for cytokine
detection in serum and SF. Clinical and demographic
data are provided, where available. Abbreviations used:
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DAS28, disease activity score of 28 joints; DMARDs,
disease-modifying anti-rheumatic drugs.
Supplementary Figure 1. PD-1 ligation reduces IFN-c
production by HC CD41 T cells but not RA or PsA
CD41 T cells. CD41 T cells from HC PBMC, RA and
PsA PBMC and SFMC were cultured in plates pre-coated
with anti-CD3 mAb (OKT3) and PD-Llfc/IgGlfc. Super-
natants were collected at day 5 and tested by ELISA for
IFN-g production. (a) IFN-g production in HC CD41 T
cell cultures in presence of PD-L1fc (0, 01 and 1 lg/m1
range; n511 and 0, 01, 1, 2 and 5 lg/m1 range; n54).
(b) IFN-g production in RA and PsA CD41 T cell cul-
tures; IA PB (RA n52; PsA n53) and IA SF (RA n52;
PsA n54). Data were analysed by Friedman Test with
Dunn’s Multiple Comparison test. *P< 005, **P< 001
and ***P< 0001.
Supplementary Figure 2. Expression of PD-1Dex3 tran-
script in activated HC CD41 T cells in presence of
TNFa and IL-6. HC CD41 T cells were cultured in
absence (medium, M) or presence of 10 ng/ml of TNFa
(n54) or IL-6 (n53) 1/- anti-TNFa (adalimumab;
ADA) or anti-IL-6R (tocilizumab; TOC) (all at 1 mg/ml)
for 5 days. PD-1Dex3 expression was examined by qPCR
and normalised to b-Actin housekeeping gene
(mean6 SEM).
Supplementary Figure 3. Proliferation of HC CD41 T
cells in presence of increasing sPD-lfc concentrations.
HC CD41 T cells (n59) were cultured with immobilised
anti-CD3 mAb (OKT3) in presence of increasing concen-
trations of sPD-lfc (0, 05 and 1 mg/ml). Proliferation was
assessed at day 5 by [3H]-thymidine incorporation and
displayed as counts per minute (cpm). Data (mean6
SEM) were analysed by Friedman Test with Dunn’s Multi-
ple Comparison test. *P< 005, **P< 001 and
***P<0001.
Supplementary Figure 4. PD-L1 expression in CD141
monocytes following IFN-c stimulation. CD141 mono-
cytes where positively isolated from HC PBMC and cul-
tured overnight at 378C in medium only or in medium
supplemented with IFN-g (10 ng/ml). PD-L1 expression
was assessed after 12 hrs by flow cytometry. (a) Represen-
tative experiment. Shaded histograms represent the iso-
type control, open histograms indicate the expression
profile for PD-L1 with/out IFN-g stimulation. (b) Cumu-
lative data (n53).
Supplementary Figure 5. PD 11 T cell frequencies are
increased in synovial fluid compared to peripheral
blood. Contour plot of CD31CD41PD-11 cells from
paired PBMC and SFMC of one representative RA donor.
FMO controls and isotype controls are shown for the
CD31CD41populations.
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